Cargando…
The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia
INTRODUCTION: Bone marrow renin–angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin treatment in AML cell lines. METHODS: AML cell lines including CESS, HL-60, MO-...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537254/ https://www.ncbi.nlm.nih.gov/pubmed/31117912 http://dx.doi.org/10.1177/1470320319851310 |
_version_ | 1783421967467020288 |
---|---|
author | Ghasemi, Mehdi Okay, Mufide Turk, Seyhan Naeemaee, Ronak Guver, Ebru Malkan, Umit Y Aksu, Salih Sayinalp, Nilgun Haznedaroglu, Ibrahim C |
author_facet | Ghasemi, Mehdi Okay, Mufide Turk, Seyhan Naeemaee, Ronak Guver, Ebru Malkan, Umit Y Aksu, Salih Sayinalp, Nilgun Haznedaroglu, Ibrahim C |
author_sort | Ghasemi, Mehdi |
collection | PubMed |
description | INTRODUCTION: Bone marrow renin–angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin treatment in AML cell lines. METHODS: AML cell lines including CESS, HL-60, MO-1, P31/FUJ, GDM-1 and KASUMI-3 were used as models in this study. RESULTS: After treating the six AML cell lines with a combination of losartan and doxorubicin, they were divided into two groups based on their behaviour: one became more sensitive to drug treatment (Group A) and the other had no change observed in behaviour after drug treatment (Group B). In silico analyses showed that Group A is involved in cellular apoptosis, while Group B is involved in tumour angiogenesis further supporting the in vitro results. CONCLUSION: The combined treatment of the AML cell lines with losartan and doxorubicin resulted in an increase in sensitivity of some of the cell lines. Those leukaemic cells are modulated via the induction of apoptosis, whereas the other cells resistant to the drug treatment are closely related to tumour angiogenesis indicating that RAS-AT1R seems to be differently expressed in different leukaemic blast cells and tumour microenvironments. Pharmaco-biological actions of RAS inhibitors may be different in distinct leukaemic cells based on the pathological behaviour of AML genomic subtypes. |
format | Online Article Text |
id | pubmed-6537254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-65372542019-06-14 The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia Ghasemi, Mehdi Okay, Mufide Turk, Seyhan Naeemaee, Ronak Guver, Ebru Malkan, Umit Y Aksu, Salih Sayinalp, Nilgun Haznedaroglu, Ibrahim C J Renin Angiotensin Aldosterone Syst Original Article INTRODUCTION: Bone marrow renin–angiotensin system(RAS) modulates acute myeloid leukaemia(AML).The aim of this study is to clarify the relationships between RAS and AML, and to show the effect of losartan and doxorubicin treatment in AML cell lines. METHODS: AML cell lines including CESS, HL-60, MO-1, P31/FUJ, GDM-1 and KASUMI-3 were used as models in this study. RESULTS: After treating the six AML cell lines with a combination of losartan and doxorubicin, they were divided into two groups based on their behaviour: one became more sensitive to drug treatment (Group A) and the other had no change observed in behaviour after drug treatment (Group B). In silico analyses showed that Group A is involved in cellular apoptosis, while Group B is involved in tumour angiogenesis further supporting the in vitro results. CONCLUSION: The combined treatment of the AML cell lines with losartan and doxorubicin resulted in an increase in sensitivity of some of the cell lines. Those leukaemic cells are modulated via the induction of apoptosis, whereas the other cells resistant to the drug treatment are closely related to tumour angiogenesis indicating that RAS-AT1R seems to be differently expressed in different leukaemic blast cells and tumour microenvironments. Pharmaco-biological actions of RAS inhibitors may be different in distinct leukaemic cells based on the pathological behaviour of AML genomic subtypes. SAGE Publications 2019-05-23 /pmc/articles/PMC6537254/ /pubmed/31117912 http://dx.doi.org/10.1177/1470320319851310 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Ghasemi, Mehdi Okay, Mufide Turk, Seyhan Naeemaee, Ronak Guver, Ebru Malkan, Umit Y Aksu, Salih Sayinalp, Nilgun Haznedaroglu, Ibrahim C The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia |
title | The impact of At1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
title_full | The impact of At1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
title_fullStr | The impact of At1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
title_full_unstemmed | The impact of At1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
title_short | The impact of At1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
title_sort | impact of at1r inhibition via losartan on the anti-leukaemic
effects of doxorubicin in acute myeloid leukaemia |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537254/ https://www.ncbi.nlm.nih.gov/pubmed/31117912 http://dx.doi.org/10.1177/1470320319851310 |
work_keys_str_mv | AT ghasemimehdi theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT okaymufide theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT turkseyhan theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT naeemaeeronak theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT guverebru theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT malkanumity theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT aksusalih theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT sayinalpnilgun theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT haznedarogluibrahimc theimpactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT ghasemimehdi impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT okaymufide impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT turkseyhan impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT naeemaeeronak impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT guverebru impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT malkanumity impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT aksusalih impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT sayinalpnilgun impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia AT haznedarogluibrahimc impactofat1rinhibitionvialosartanontheantileukaemiceffectsofdoxorubicininacutemyeloidleukaemia |